論文

2020年7月

Human papillomavirus genotype contribution to cervical cancer and precancer: Implications for screening and vaccination in Japan

CANCER SCIENCE
  • Mamiko Onuki
  • Koji Matsumoto
  • Takashi Iwata
  • Kasumi Yamamoto
  • Yoichi Aoki
  • Shoji Maenohara
  • Naotake Tsuda
  • Shoji Kamiura
  • Kazuhiro Takehara
  • Koji Horie
  • Nobutaka Tasaka
  • Hideaki Yahata
  • Yuji Takei
  • Hisamori Kato
  • Takeshi Motohara
  • Keiichiro Nakamura
  • Mitsuya Ishikawa
  • Tatsuya Kato
  • Hiroyuki Yoshida
  • Noriomi Matsumura
  • Hidekatsu Nakai
  • Shogo Shigeta
  • Fumiaki Takahashi
  • Kiichiro Noda
  • Nobuo Yaegashi
  • Hiroyuki Yoshikawa
  • 全て表示

111
7
開始ページ
2546
終了ページ
2557
記述言語
英語
掲載種別
研究論文(学術雑誌)
DOI
10.1111/cas.14445
出版者・発行元
WILEY

To obtain baseline data for cervical cancer prevention in Japan, we analyzed human papillomavirus (HPV) data from 5045 Japanese women aged less than 40 years and diagnosed with cervical abnormalities at 21 hospitals during 2012-2017. These included cervical intraepithelial neoplasia grade 1 (CIN1, n = 573), CIN2-3 (n = 3219), adenocarcinoma in situ (AIS, n = 123), and invasive cervical cancer (ICC, n = 1130). The Roche Linear Array was used for HPV genotyping. The HPV type-specific relative contributions (RCs) were estimated by adding multiple infections to single types in accordance with proportional weighting attributions. Based on the comparison of type-specific RCs between CIN1 and CIN2-3/AIS/ICC (CIN2+), RC ratios were calculated to estimate type-specific risks for progression to CIN2+. Human papillomavirus DNA was detected in 85.5% of CIN1, 95.7% of CIN2-3/AIS, and 91.2% of ICC. Multiple infections decreased with disease severity: 42.9% in CIN1, 40.4% in CIN2-3/AIS, and 23.7% in ICC (P < .0001). The relative risk for progression to CIN2+ was highest for HPV16 (RC ratio 3.78, 95% confidence interval [CI] 3.01-4.98), followed by HPV31 (2.51, 1.54-5.24), HPV18 (2.43, 1.59-4.32), HPV35 (1.56, 0.43-8.36), HPV33 (1.01, 0.49-3.31), HPV52 (0.99, 0.76-1.33), and HPV58 (0.97, 0.75-1.32). The relative risk of disease progression was 1.87 (95% CI, 1.71-2.05) for HPV16/18/31/33/35/45/52/58, but only 0.17 (95% CI, 0.14-0.22) for HPV39/51/56/59/66/68. Human papillomavirus 16/18/31/33/45/52/58/6/11 included in a 9-valent vaccine contributed to 89.7% (95% CI, 88.7-90.7) of CIN2-3/AIS and 93.8% (95% CI, 92.4-95.3) of ICC. In conclusion, our data support the Japanese guidelines that recommend discriminating HPV16/18/31/33/35/45/52/58 genotypes for CIN management. The 9-valent vaccine is estimated to provide over 90% protection against ICC in young Japanese women.

リンク情報
DOI
https://doi.org/10.1111/cas.14445
Web of Science
https://gateway.webofknowledge.com/gateway/Gateway.cgi?GWVersion=2&SrcAuth=JSTA_CEL&SrcApp=J_Gate_JST&DestLinkType=FullRecord&KeyUT=WOS:000534418400001&DestApp=WOS_CPL
ID情報
  • DOI : 10.1111/cas.14445
  • ISSN : 1347-9032
  • eISSN : 1349-7006
  • Web of Science ID : WOS:000534418400001

エクスポート
BibTeX RIS